Fig. 5

Blocking IL6 signaling enhances the antitumor activity of NK cells in HPV − tumors. A, B Percent of CD8⁺ T cells and CD161⁺ NK cells in MOC2 tumors treated with isotype or αIL6. C Percent of Ki67⁺ NK cells in MOC2 tumors treated with isotype or αIL6. D, E Percent of CD8⁺ T cells and CD161⁺ NK cells in TC-1 tumors treated with isotype or αIL6. F Percent of Ki67⁺ NK cells in TC-1 tumors treated with isotype or αIL6. G Immunofluorescence staining of anti-CD161 antibody in MOC2 and TC-1 tumors treated with isotype or αIL6. Representative images and quantitative data are shown in the left and right panels. In (A, B, D, E), T cells and NK cells were gated from CD3⁺ and CD3⁻ population, respectively. *p < 0.05; **p < 0.01; ns: not significant